These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 23706716

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
    Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
    [Abstract] [Full Text] [Related]

  • 3. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, Munzu C, Koehne-Voss S, Rivière GJ, Kaiser G, Erpenbeck VJ.
    Int Arch Allergy Immunol; 2013 Jul; 160(1):102-10. PubMed ID: 22948442
    [Abstract] [Full Text] [Related]

  • 4. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW, Guerriero M, Micheletto C, Tognella S, Visconti M.
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N, Comas Sugrañes D, Méndez Cabaleiro N, Figueras Suriol A, Jodar Masanes R.
    Farm Hosp; 2013 Jun; 37(5):399-405. PubMed ID: 24128103
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C, Spanish Registry.
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group.
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O, Komori C, Hang Y, Matsumoto T, Minamoto S.
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [Abstract] [Full Text] [Related]

  • 12. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [Abstract] [Full Text] [Related]

  • 13. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D, Talker O, Metabichek A, Yaakovi I.
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [Abstract] [Full Text] [Related]

  • 15. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.
    J Biol Regul Homeost Agents; 2011 Jul; 25(2):177-86. PubMed ID: 21880206
    [Abstract] [Full Text] [Related]

  • 16. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [Abstract] [Full Text] [Related]

  • 17. Association between consistent omalizumab treatment and asthma control.
    Lafeuille MH, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P.
    J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES, Özge C, Ïlvan A, Naycı SA.
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.